

Stay ahead of the curve: How AI is reshaping ophthalmology trials at every stage



A KEY QUESTION



How can AI in ophthalmology transform each critical stage of your trial journey—and what are the actionable advantages you need to stay ahead?

KEYWORDS

Ophthalmology, Artificial Intelligence, Clinical Trial, Machine Learning, Diagnostics

The ophthalmology clinical research landscape is experiencing a seismic shift. Artificial intelligence (AI) isn't just knocking on the door—it's revolutionizing how we design, execute and analyze trials from the ground up. The use of AI in ophthalmology is already demonstrating robust performance in detecting diabetic retinopathy, macular edema and age-related macular degeneration.^{1,2}

For clinical research directors, understanding where AI and ophthalmology intersect to deliver impact across your trial lifecycle isn't just advantageous—it's essential for staying competitive. Machine learning in ophthalmology has achieved accuracy comparable to human specialists, streamlining screening, diagnosis and monitoring in both clinical and telemedicine settings.³⁻⁶

The promise is compelling: smarter patient identification, more precise diagnostics and data analysis that uncovers invisible patterns. But implementing AI and machine learning in clinical trials requires strategic navigation through technology choices, regulatory considerations and operational integration.

Let's explore how AI in ophthalmology transforms each critical stage of your trial journey—actionable advantages and the decisive edge you need to stay ahead.

1

Protocol development: Design that wins

The days of guesswork and endless revisions could be over. AI-driven predictive modeling lets you simulate trial scenarios using decades of clinical and imaging data, exposing risks and optimizing protocols before launch.

- **Predictive endpoint selection:** Machine learning analyzes vast data sets of patient outcomes and disease progression patterns to identify optimal primary and secondary endpoints that are both clinically meaningful and achievable within realistic timelines^{6,7}
- **Precise sample size calculations:** Real-world data from health records and imaging determines optimal sample sizes, reducing costly amendments and lengthy redesigns—critical when development costs continue to climb^{8,9}
- **Optimized inclusion criteria:** AI analyzes historical screening patterns to predict which eligibility criteria changes will improve enrollment rates while maintaining target population characteristics¹⁰
- **Disease trajectory modeling:** For conditions like geographic atrophy and diabetic retinopathy, AI models forecast how individual patients' conditions will likely progress, supporting more informed study design and optimized trial timelines^{11,12}

You gain protocols that are smarter, faster and more likely to succeed—providing a competitive edge while reducing development time.^{6,7}

- **Predictive enrollment modeling:** Machine learning evaluates patient flow patterns, referral networks and local factors like seasonal variations to identify sites with the highest likelihood of meeting enrollment targets within timelines⁷
- **Dynamic performance optimization:** Real-time monitoring enables AI systems to identify sites needing additional support and suggest protocol amendments that improve overall study efficiency¹³

This isn't theoretical. Human-enabled AI is already delivering tangible results, improving recruitment rates by up to 26% and reducing time to first patient by 24%. **You hit your milestones sooner and maximize ROI** while others struggle with slow-to-enroll studies.⁷



2

Site selection: Recruiting where it counts

Your site selection decisions can make or break a trial's success. AI platforms analyze performance data, demographics and patient volumes across thousands of global trial sites to pinpoint where your specific patient populations are most accessible.

3

Patient identification: Fueling your pipeline

Traditional approaches to patient identification can't keep up with today's demands. AI turbocharges your recruitment by mining real-world electronic health records, imaging and unstructured data sets to instantly flag eligible candidates.

- **Dramatic screen failure reduction:** AI can pre-screen patients using existing medical records and imaging data, improving screen failure rates from typical 50%+ to significantly lower levels by identifying truly eligible patients before clinic visits—reducing both patient and site burden and screen failure costs¹⁰
- **Superhuman diagnostic accuracy:** The FDA-authorized IDx-DR system—the first autonomous diagnostic AI device in medicine—screens for diabetic retinopathy in primary care, delivering 87.2% sensitivity and 90.7% specificity—consistently outperforming human observers and eliminating subtle disease characteristics that might be missed^{14,15}

Imagine this level of precision: the right patients, identified in minutes instead of weeks, arriving ready for enrollment with dramatically reduced screening costs.

4

Enhanced diagnostic accuracy: Unlocking gold-standard consistency

Quality and reliability drive competitive differentiation, and AI is redefining what's possible. Deep learning models now analyze fundus images and Optical Coherence Tomography (OCT) scans as effectively as top human experts, achieving diagnostic accuracy exceeding 87% for conditions like diabetic retinopathy and macular degeneration.^{3-5,14}

- **Elimination of inter-observer variability:** AI provides consistent interpretations of OCT scans, fundus photographs and diagnostic images across all trial sites, regardless of equipment or timing—dramatically improving your data integrity^{4,16}
- **Multi-center standardization:** AI compensates for variations in imaging equipment, protocols and reader expertise across international trial sites by normalizing images to standard parameters, making global trials as consistent as single-center studies^{3,6}

- **Real-time quality control:** Algorithms instantly flag substandard images during acquisition, enabling recapture during patient visits rather than discovering issues during later central review—reducing both patient and site burden and increasing patient retention⁴⁻⁶

You need confidence in your data. AI delivers that by eliminating diagnostic variability, standardizing imaging across global sites and flagging quality issues in real time—**so your trials run smoother, faster and with greater integrity.**

5 Patient retention and adherence: Keeping your trials on track

Patient dropouts can derail even the most promising trial, but AI gives you cutting-edge tools to support them. Every retained patient bolsters statistical power, reduces costs and enhances your reputation for running patient-centric, successful trials.

- **Intelligent patient prioritization:** AI analyzes clinical characteristics, adherence potential and real-time disease progression to focus screening on patients most likely to complete studies and those at optimal disease stages for specific interventions¹⁷
- **Dropout predictions:** AI combines personalized risk scoring with smart scheduling, identifying patients at higher risk of dropout based on factors like travel distance, treatment history and social determinants, while optimizing visit timing using preferences and attendance patterns—which is especially important for chronic conditions like glaucoma and diabetic retinopathy^{11,13}
- **Automated engagement tools:** Personalized messaging systems powered by AI deliver targeted reminders and support, boosting retention⁶

AI-driven retention strategies help safeguard your investment by identifying **high-adherence patients, predicting dropouts and automating personalized engagement**—helping your trials stay on track, on budget and statistically sound.

6 Data collection: Driving consistency, speed and quality

The explosion of high-resolution imaging data demands solutions beyond manual oversight. AI brings real-time, automated quality control that transforms how you manage trial data integrity.

- **Real-time anomaly detection:** Machine learning continuously analyzes incoming data streams to identify protocol deviations, data entry errors and emerging safety signals before they impact study integrity^{8,13}

- **Deeper patient insights:** Natural language processing uncovers key themes and concerns from free-text patient responses that structured questionnaires miss—providing richer context for interpreting clinical endpoints and enhancing patient-centric trial design¹⁷

Across multi-center, global studies, this means **unprecedented standardization, fewer delays and consistent, high-quality data sets** that regulators and sponsors' trust.

7 Study closure and data analysis: Reveal insights that move the needle

When the last patient finishes, the clock is ticking and AI delivers. Automated quality checks, outlier identification and preliminary analyses compress your analysis timelines, reducing study closure by weeks or months while maintaining data integrity.

- **AI-enabled discovery:** High-resolution morphological analysis by machine learning uncovers subtle, actionable biomarker patterns invisible to traditional analytics, surfacing signals for disease progression or therapeutic efficacy early in the review process^{4,6}
- **Comprehensive imaging analysis:** AI performs analyses of massive imaging data sets that would be impossible manually, identifying biomarkers that correlate with treatment response and predict long-term outcomes—creating competitive advantages for your drug development program^{5,18}

Speed and insight at study closeout are critical. AI accelerates your timelines by automating quality checks and surfacing subtle biomarker patterns—**giving you faster, deeper visibility into therapeutic impact and competitive advantage.**

8 Regulatory submission: Setting the standard

Regulatory scrutiny is rising, especially around AI “black box” solutions. The good news? FDA clearance of IDx-DR offers a proven blueprint for future advancements.^{14,15}

- **Robust supporting evidence:** AI analyses provide multiple analytical approaches demonstrating treatment effects, strengthening regulatory submissions with objective, reproducible data that reviewers can trust^{14,15}
- **Elimination of interpretation bias:** Standardized, objective AI-generated endpoints remove concerns about inter-observer variability and subjective interpretation, potentially making endpoints more reliable than traditional human-interpreted measures¹⁶
- **Proactive regulatory preparation:** AI identifies potential regulatory concerns before submission by analyzing data patterns that might raise questions about study conduct or treatment effects, helping you address issues before they become problems^{8,19}

Regulatory confidence is everything. **AI strengthens your submissions** with objective, reproducible data, eliminates interpretation bias and flags potential concerns early—helping you meet rising standards and move forward with fewer surprises.

Why this matters now—and how Fortrea helps you lead

This isn't evolution—it's transformation. The clinical research director who harnesses this transformative leap will set the pace for the next decade. Ethical and operational challenges remain, but with the right collaborations, you have a clear pathway to responsible deployment that protects data privacy, enables algorithmic fairness and builds regulatory confidence.

Fortrea is dedicated to being your trusted navigator, helping you navigate the future of AI-driven ophthalmology trials. Let's collaborate to operationalize AI at every stage of your ophthalmology trial, so you can move faster, recruit smarter, deliver cleaner data and lead in today's high-stakes environment.

Better together. Better tomorrow.



[Get in touch](#) with the Ophthalmology team at Fortrea to learn more.



References

1. Li Z, Wang L, Wu X, et al. Artificial intelligence in ophthalmology: The path to the real-world clinic. *Cell Rep Med*. 2023;4(7):101095. doi:10.1016/j.xcrm.2023.101095
2. Artificial Intelligence in Neuro-Ophthalmology - EyeWiki. *Eyewiki.org*. Published December 19, 2023. Accessed August 5, 2025. https://eyewiki.org/Artificial_Intelligence_in_Neuro-Ophthalmology
3. Ting SW, Pasquale LR, Peng L, et al. Artificial intelligence and deep learning in ophthalmology. *Br J Ophthalmol*. 2019;103(2):167-175. doi:10.1136/bjophthalmol-2018-313173
4. Schmit-Erfurth U, Sadeghipour A, Gerendas BS, et al. Artificial intelligence in retina. *Prog Retin Eye Res*. 2018;67:1-29. doi:10.1016/j.preteyeres.2018.07.004
5. Lee C, Tying AJ, Deruyter NP, et al. Deep learning is effective for classifying normal versus age-related macular degeneration OCT images. *Ophthalmol Retina*. 2017;1(4):322-327. doi:10.1016/j.oret.2016.12.009
6. Li JO, iu H, Ting DSJ, et al. Digital technology, tele-medicine, and artificial intelligence in ophthalmology: A global perspective. *Prog Retin Eye Res*. 2021;82:100900. doi:10.1016/j.preteyeres.2020.100900
7. Clinical Trial Vanguard. Human-enabled AI driving enhancements in clinical trial site selection. *Clinical Trial Vanguard*. Published 2024. Accessed July 9, 2025. <https://www.clinicaltrialvanguard.com/article/human-enabled-ai-driving-enhancements-in-clinical-trial-site-selection>
8. Yang WH, Shao Y, Xu YW; Expert Workgroup of Guidelines on Clinical Research Evaluation of Artificial Intelligence in Ophthalmology (2023), Ophthalmic Imaging and Intelligent Medicine Branch of Chinese Medicine Education Association, Intelligent Medicine Committee of Chinese Medicine Education Association. Guidelines on clinical research evaluation of artificial intelligence in ophthalmology (2023). *Int J Ophthalmol*. 2023;16(9):1361-1372. Published 2023 Sep 18. doi:10.18240/ijo.2023.09.02
9. Lakhani P, Prater AB, Hutson RK, et al. Machine Learning in Radiology: Applications Beyond Image Interpretation. *J Am Coll Radiol*. 2018;15(2):350-359. doi:10.1016/j.jacr.2017.09.044
10. Williamson DJ, Struyven RR, Antaki F, et al. Artificial Intelligence to Facilitate Clinical Trial Recruitment in Age-Related Macular Degeneration. *Ophthalmol Sci*. 2024;4(6):100566. Published 2024 Jun 19. doi:10.1016/j.xops.2024.100566
11. Yim J, Chopra R, Spitz T, et al. Predicting conversion to wet age-related macular degeneration using deep learning. *Nat Med*. 2020;26(6):892-899. doi:10.1038/s41591-020-0867-7
12. Rohm M, Tresp V, Müller M, et al. Predicting Visual Acuity by Using Machine Learning in Patients Treated for Neovascular Age-Related Macular Degeneration. *Ophthalmology*. 2018;125(7):1028-1036. doi:10.1016/j.ophtha.2017.12.034
13. Sendak MP, Ratliff W, Sarro D, et al. Real-World Integration of a Sepsis Deep Learning Technology Into Routine Clinical Care: Implementation Study. *JMIR Med Inform*. 2020;8(7):e15182. Published 2020 Jul 15. doi:10.2196/15182
14. Abràmoff MD, Lavin PT, Birch M, et al. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. *NPJ Digit Med*. 2018;1:39. doi:10.1038/s41746-018-0040-6
15. Wong TY, Bressler NM. Artificial intelligence with deep learning technology looks into diabetic retinology screening. *JAMA*. 2016;316(22):2366-2367. <https://pubmed.ncbi.nlm.nih.gov/27898977/>
16. Liu X, Faes L, Kale AU, et al. A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. *Lancet Digit Health*. 2019;1(6):e271-e297. doi:10.1016/S2589-7500(19)30123-2
17. Shameer K, Johnson KW, Glicksberg BS, Dudley JT, Sengupta PP. Machine learning in cardiovascular medicine: are we there yet?. *Heart*. 2018;104(14):1156-1164. doi:10.1136/heartjnl-2017-311198
18. Varadarajan AV, Poplin R, Blumer K, et al. Deep Learning for Predicting Refractive Error From Retinal Fundus Images. *Invest Ophthalmol Vis Sci*. 2018;59(7):2861-2868. doi:10.1167/iovs.18-23887
19. Weiner E, Dankwa-Mullan I, Nelson W, et al. Ethical challenges and evolving strategies in the integration of artificial intelligence into clinical practice. *PLOS Digit Health*. 2025;4(4):e0000810. doi:10.1371/journal.pdig.0000810